Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptist Gallwitz

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
MMW Fortschritte Der Medizin|October 19, 2023
[Type-2-Diabetes: choosing antidiabetic therapy depending on comorbidities]Baptist Gallwitz
MMW Fortschritte Der Medizin|October 17, 2014
[Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?]Baptist Gallwitz
Innere Medizin (Heidelberg, Germany)|January 4, 2023
[Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases]Baptist Gallwitz
Pharmazie in Unserer Zeit|March 3, 2010
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]Baptist Gallwitz
Pediatric Nephrology (Berlin, Germany)|February 5, 2010
The evolving place of incretin-based therapies in type 2 diabetesBaptist Gallwitz
Idrugs : the Investigational Drugs Journal|December 4, 2008
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesBaptist Gallwitz
Drugs of Today (Barcelona, Spain : 1998)|February 23, 2007
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetesBaptist Gallwitz
Endocrine|March 8, 2014
Extra-pancreatic effects of incretin-based therapiesBaptist Gallwitz
Clinical Medicine Insights. Endocrinology and Diabetes|August 11, 2012
Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapyBaptist Gallwitz
Drugs|September 10, 2011
Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agentsBaptist Gallwitz
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
MMW Fortschritte Der Medizin|October 19, 2023
[Type-2-Diabetes: choosing antidiabetic therapy depending on comorbidities]Baptist Gallwitz
MMW Fortschritte Der Medizin|October 17, 2014
[Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?]Baptist Gallwitz
Innere Medizin (Heidelberg, Germany)|January 4, 2023
[Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases]Baptist Gallwitz
Pharmazie in Unserer Zeit|March 3, 2010
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]Baptist Gallwitz
Pediatric Nephrology (Berlin, Germany)|February 5, 2010
The evolving place of incretin-based therapies in type 2 diabetesBaptist Gallwitz
Idrugs : the Investigational Drugs Journal|December 4, 2008
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesBaptist Gallwitz
Drugs of Today (Barcelona, Spain : 1998)|February 23, 2007
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetesBaptist Gallwitz
Endocrine|March 8, 2014
Extra-pancreatic effects of incretin-based therapiesBaptist Gallwitz
Clinical Medicine Insights. Endocrinology and Diabetes|August 11, 2012
Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapyBaptist Gallwitz
Drugs|September 10, 2011
Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agentsBaptist Gallwitz
Pageof 13